EMA fast-tracks Marinus Pharma’s rare epilepsy treatment

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved Marinus Pharmaceuticals’ request for accelerated assessment of its lead product candidate, ganaxolone, for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy.